Business Description
TransCode Therapeutics Inc. is a Boston-based biopharmaceutical company founded in 2016 that develops treatments and diagnostic tools for cancer. Its most advanced drug candidate, TTX-MC138, targets a key molecule involved in the spread of cancer across multiple tumor types, including breast, pancreatic, and ovarian cancers. The company is also advancing a range of earlier-stage programs that use RNA and gene-editing technologies to attack tumors in different ways, and it works in partnership with MD Anderson Cancer Center to support its research efforts.
